Literature DB >> 7536501

Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3.

T Tsujimura1, T Furitsu, M Morimoto, Y Kanayama, S Nomura, Y Matsuzawa, Y Kitamura, Y Kanakura.   

Abstract

The c-kit protooncogene encodes a receptor tyrosine kinase that mediates signals required for differentiation, proliferation and survival of mast cells. We have already shown the constitutive activation of c-kit receptor tyrosine kinase (KIT) in a human mast cell leukemia line (HMC-1) and a murine mastocytoma cell line (P-815). We here examined whether such constitutive activation of KIT occurred in the rat tumor mast cell line RBL-2H3 as well, which is frequently used as a tool for studying functions of mast cells. In RBL-2H3 cells, KIT was constitutively phosphorylated on tyrosine and activated in the absence of autocrine production of its ligand, stem cell factor (SCF). Sequencing analysis revealed that one of c-kit genes of RBL-2H3 cells had a point mutation, resulting in amino acid substitution of Tyr for Asp in codon 817. When rat wild-type c-kit cDNA and mutant-type c-kit cDNA encoding KITTyr817 were transfected into cells of a human embryonic kidney cell line (293T), only mutant form KITTyr817 was constitutively phosphorylated on tyrosine and activated in the absence of SCF. Since mutations at the same Asp codon constitutively activated KIT in all the human HMC-1, murine P-815, and rat RBL-2H3 cell lines, and since the incorporation of antisense oligonucleotides of c-kit messenger RNA significantly suppressed the proliferation of RBL-2H3 cells, the activating mutations in the Asp codon of the c-kit gene appeared to be involved in neoplastic growth of mast cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536501     DOI: 10.1159/000236870

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  21 in total

1.  KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.

Authors:  Youl-Nam Lee; Stephanie Brandal; Pierre Noel; Erik Wentzel; Joshua T Mendell; Michael A McDevitt; Reuben Kapur; Melody Carter; Dean D Metcalfe; Clifford M Takemoto
Journal:  Blood       Date:  2011-01-27       Impact factor: 22.113

2.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

Authors:  M L Lux; B P Rubin; T L Biase; C J Chen; T Maclure; G Demetri; S Xiao; S Singer; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 3.  The RBL-2H3 cell line: its provenance and suitability as a model for the mast cell.

Authors:  Egle Passante; Neil Frankish
Journal:  Inflamm Res       Date:  2009-08-09       Impact factor: 4.575

4.  A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain.

Authors:  L P Lam; R Y Chow; S A Berger
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

5.  Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.

Authors:  Alison C Macleod; Lillian R Klug; Janice Patterson; Diana J Griffith; Carol Beadling; Ajia Town; Michael C Heinrich
Journal:  Mol Cancer Ther       Date:  2014-09-24       Impact factor: 6.261

Review 6.  Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing.

Authors:  Jeffrey Douaiher; Julien Succar; Luca Lancerotto; Michael F Gurish; Dennis P Orgill; Matthew J Hamilton; Steven A Krilis; Richard L Stevens
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

7.  Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.

Authors:  Zhifu Xiang; Frederike Kreisel; Jennifer Cain; AnnaLynn Colson; Michael H Tomasson
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

8.  Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

Authors:  Joseph D Growney; Jennifer J Clark; Jennifer Adelsperger; Richard Stone; Doriano Fabbro; James D Griffin; D Gary Gilliland
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

9.  The Src family kinase Fgr is critical for activation of mast cells and IgE-mediated anaphylaxis in mice.

Authors:  Jun Ho Lee; Jie Wan Kim; Do Kyun Kim; Hyuk Soon Kim; Hye Jin Park; Dong Ki Park; A-Ram Kim; Bokyung Kim; Michael A Beaven; Kui Lea Park; Young Mi Kim; Wahn Soo Choi
Journal:  J Immunol       Date:  2011-07-11       Impact factor: 5.422

10.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.

Authors:  B J Longley; D D Metcalfe; M Tharp; X Wang; L Tyrrell; S Z Lu; D Heitjan; Y Ma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.